OakChart

Dyadic International Inc, DE

DYAIHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 4:00 PM ET

0.3880+0.0220 (6.01%)
2026-11-11 22:20 CET
Market cap
14.66 USD m
Revenue, TTM
3.80 USD m
Net income, TTM
-7.62 USD m
Free cash flow, TTM
-7.40 USD m
EPS diluted, TTM
-0.21
P/E
-
Compare

Price

DYAI against its 20, 50 and 200-day averages
2050200missearnings
0.501.001.504.3M8.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DYAIclose 0.3920-day 0.3850-day 0.42200-day 0.740.3952w high

75.8% under the 52-week high of 1.60 on 22 Jul 2026. 52-week low 0.33 on 5 Nov 2026. Last 15 sessions, 42.4% high to low

Volume 0.28× normal · the line is the 50-bar volume average

Profile

DYAI
52-week range, 5% of the way up
0.331.60

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.

Employees5
IPONov 05, 2004
Beta1.08
ATR, 14d0.04
Rel volume0.28
Short float0.27%
Insider own23.02%
Inst own20.20%

Snapshot

6 groups

Valuation

Index-
Market Cap15.54M
Enterprise Value15.92M
Income-7.62M
Sales3.80M
Book/sh-0.07
Cash/sh0.12
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPONov 05, 2004

Ratios

P/E-
Forward P/E12.93
PEG0.20
P/S4.09
P/B-
P/C3.33
P/FCF-
EV/EBITDA-
EV/Sales4.19
Quick Ratio1.65
Current Ratio1.65
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.21
EPS next Y0.03
EPS next Q-0.04
EPS this Y39.13%
EPS next Y121.43%
EPS next 5Y64.84%
EPS past 3/5Y13.04% 7.84%
Sales past 3/5Y1.79% 14.04%
EPS Y/Y TTM-14.12%
Sales Y/Y TTM-8.05%
EPS Q/Q2.18%
Sales Q/Q-0.57%
EarningsNov 12 AMC
EPS/Sales Surpr.-71.43% -6.28%

Ownership

Insider Own23.02%
Insider Trans-2.83%
Inst Own20.20%
Inst Trans-2.92%
ROA-103.88%
ROE-2826.92%
ROIC-287.21%
Gross Margin16.24%
Oper. Margin-194.50%
Profit Margin-200.46%
SMA201.32%
SMA50-8.24%
SMA200-47.58%
Trades-

Technical

Shs Outstand36.44M
Shs Float30.84M
Short Float0.27%
Short Ratio0.54
Short Interest0.08M
52W High1.60 -75.75%
52W Low0.33 17.58%
Volatility10.50% 10.28%
ATR (14)0.04
RSI (14)47.10
Beta1.08
Rel Volume0.28
Avg Volume155.20K
Volume44,162

Performance

Perf Week5.81%
Perf Month-8.77%
Perf Quarter-49.62%
Perf Half Y-45.39%
Perf YTD-58.72%
Perf Year-60.31%
Perf 3Y-76.63%
Perf 5Y-90.35%
Perf 10Y-76.48%
Recom1.00
Target Price5.50
Prev Close0.37
Price0.39
Change %6.01%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Oct 23, 2025ResumedHH.C. WainwrightBuy$3+673.2%
Sep 08, 2025InitiatedCCraig HallumBuy
Jul 18, 2022DowngradeDDawson JamesBuy → Neutral
Dec 17, 2021InitiatedHH.C. WainwrightBuy$7+1,704.1%

Peers

Mkt cap
TickerCompanyMkt cap
CDXSCodexis Inc106.93M
OABIOmniAb Inc743.89M
EXOZeXoZymes Inc37.50M
IBIOiBio Inc50.16M
ABSIAbsci Corp1.73B
DNAGinkgo Bioworks Holdings Inc679.14M
MLECMoolec Science SA0.62M
PLXProtalix BioTherapeutics Inc252.18M
CLGNCollPlant Biotechnologies Ltd7.48M
EVGNEvogene Ltd6.69M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Francisco Trust under agreemen10% OwnerJul 23 '26Sale1.3054,76071,3033,282,888Jul 24 05:11 PM
Francisco Trust under agreemen10% OwnerJul 22 '26Sale1.3338,01650,4813,337,648Jul 24 05:11 PM
Francisco Trust under agreemen10% OwnerJul 24 '26Sale1.212,6163,1733,280,272Jul 24 05:11 PM
Francisco Trust under agreemenGreater than 10% holderJul 21 '26Proposed Sale1.48364,387539,296Jul 21 05:52 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S. (GlobeNewswire)
  • Dyadic's Q3 Report Must Show Its Cash Lifeline Before Its Product Ramp (Earnings Whispers)
  • Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026 (GlobeNewswire) +5.32%
  • iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026 (ACCESSWIRE)
  • Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -12.49%
  • Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ... (GuruFocus.com)
  • Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas (GlobeNewswire) -16.19%
  • Earnings To Watch: Dyadic International Inc (DYAI) Q2 2026 -- GF Value Sees 40% Downside (GuruFocus.com) +5.51%
  • Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement (GlobeNewswire)
  • Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026 (GlobeNewswire)
  • Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days (GlobeNewswire) -6.19%
  • Dyadic Announces Continued Listing on the Nasdaq Capital Market (GlobeNewswire)
  • Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program (GlobeNewswire)
  • Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential (GlobeNewswire) +9.55%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.045--1.432
2026Q22026-08-12-0.060-0.035-0.0600.961.032
2026Q12026-05-13-0.050-0.040-0.0541.110.901
2025Q42026-03-25-0.040-0.045-0.0430.561.342
2025Q32025-11-12-0.060-0.044-0.0571.161.222
2025Q22025-08-13-0.060-0.060-0.0600.970.601
2025Q12025-05-14-0.070--0.0680.39--
2024Q42025-03-26-0.050-0.040-0.0520.821.602
2024Q32024-11-12-0.010-0.070-0.0071.961.101
2024Q22024-08-13-0.070-0.065-0.0700.391.002
2024Q12024-05-14-0.070--0.0700.33--
2023Q42024-03-28-0.080-0.065-0.0720.680.802
2023Q32023-11-08-0.060-0.060-0.0560.401.202
2023Q22023-08-09-0.070-0.050-0.0750.841.302
2023Q12023-05-10-0.030--0.0330.98--
2022Q42023-03-29-0.070-0.070-0.0750.741.452

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-0.210-0.250-0.2061.300.77
2019FY-0.310-0.320-0.3081.681.63
2020FY-0.340-0.350-0.3391.601.16
2021FY-0.470-0.357-0.4702.402.27
2022FY-0.340-0.340-0.3432.933.65
2023FY-0.240-0.230-0.2362.903.05
2024FY-0.200-0.180-0.1983.504.30
2025FY-0.230-0.225-0.2303.093.86
2026FY--0.140--6.51
2027FY-0.030--12.51
2028FY--0.010--11.00
2029FY-0.240--19.74

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-262001.431.301.57
2026Q3S2026-08-122011.431.301.57
2026Q3S2026-07-282001.511.301.72
2026Q3S2026-05-192011.511.301.72
2026Q3S2026-05-141011.721.721.72
2026Q3S2026-03-261101.861.861.86
2026Q3S2026-01-271001.821.821.82
2026Q3S2025-11-131011.821.821.82
2026Q3S2025-11-111002.202.202.20
2026Q3S2025-11-101002.202.202.20
2026Q3S2025-11-091002.202.202.20
2026Q3S2025-11-081002.202.202.20
2026Q3S2025-11-071002.202.202.20
2026Q3S2025-11-061002.202.202.20

Estimate history

EPS, annual-0.07-0.206-0.308-0.339-0.47-0.343-0.236-0.198-0.226-0.2126
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.07-0.007-0.052-0.068-0.06-0.057-0.043-0.054-0.058
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.7581.2951.6811.6022.4042.932.8993.4953.093.8
Period201720182019202020212022202320242025TTM
Sales, quarterly0.3861.9580.8170.3940.9671.1650.5661.1110.961
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual28.32826.71327.35927.49428.22928.56328.81129.83636.18836.439
Period201720182019202020212022202320242025MRQ
Shares, quarterly29.47829.58929.83630.09130.13636.18836.18836.43936.439
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue3.803.093.502.902.932.401.601.681.30
Cost of Goods Sold Incl. D&A3.182.321.191.982.121.941.421.461.03
Gross Profit0.620.772.300.920.810.460.180.220.27
Selling, General and Administrative Excl. Other8.017.928.189.1110.9215.0910.149.487.84
Research and Development1.842.152.043.304.508.393.873.963.32
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-7.40-7.15-5.88-8.19-10.12-14.63-9.96-9.25-7.57
Interest Expense0.450.460.430.000.000.000.000.000.00
Unusual Expense0.000.000.000.00-0.250.00-0.280.000.00
Net Income Before Taxes-7.62-7.36-5.81-6.80-9.74-13.07-9.29-8.30-6.70
Income Taxes0.000.000.000.000.000.000.030.01-1.01
Consolidated Net Income-7.62-7.36-5.81-6.80-9.74-13.07-9.33-8.31-5.69
Net Income From Continuing Operations-7.62-7.36-5.81-6.80-9.74-13.07-9.33-8.31-5.69
Net Income-7.62-7.36-5.81-6.80-9.74-13.07-9.33-8.31-5.69
EPS (Recurring)-0.21-0.23-0.20-0.24-0.35-0.47-0.35-0.31-0.21
EPS (Basic, Before Extraordinaries)-0.21-0.23-0.20-0.24-0.34-0.47-0.34-0.31-0.21
EPS (Diluted)-0.21-0.23-0.20-0.24-0.34-0.47-0.34-0.31-0.21
EBITDA-7.40-7.15-5.88-8.19-10.12-14.63-9.96-9.25-7.57
Non-Operating Income (Expense)0.220.240.501.400.131.560.380.960.87
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.650.931.131.241.891.781.210.850.37
Price To Sales Ratio8.599.9214.6815.9911.9152.3492.2683.2140.37
Gross Margin16.2424.9365.8231.8427.5419.1111.0513.1720.70
Operating Margin-194.50-231.23-168.17-282.58-345.21-608.64-621.96-550.53-584.48
Net Margin-200.46-238.31-166.19-234.42-332.23-543.73-582.13-494.21-439.36
Shares Outstanding36.4436.1929.8428.8128.5628.2327.4927.3626.71
Market Capitalization14.6614.6651.7846.3935.13126.92147.85140.9664.53

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.961.110.571.160.970.390.821.96
Cost of Goods Sold Incl. D&A0.980.790.381.020.610.300.350.40
Gross Profit-0.020.320.180.140.350.100.461.56
Selling, General and Administrative Excl. Other2.022.231.712.052.072.091.991.76
Research and Development0.330.480.460.570.630.490.550.46
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.05-1.91-1.52-1.91-1.71-2.00-1.52-0.20
Interest Expense0.110.110.110.110.110.110.130.13
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-2.12-1.95-1.57-1.98-1.79-2.03-1.55-0.20
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.12-1.95-1.57-1.98-1.79-2.03-1.55-0.20
Net Income From Continuing Operations-2.12-1.95-1.57-1.98-1.79-2.03-1.55-0.20
Net Income-2.12-1.95-1.57-1.98-1.79-2.03-1.55-0.20
EPS (Recurring)-0.06-0.05-0.04-0.06-0.06-0.07-0.05-0.01
EPS (Basic, Before Extraordinaries)-0.06-0.05-0.04-0.06-0.06-0.07-0.05-0.01
EPS (Diluted)-0.06-0.05-0.04-0.06-0.06-0.07-0.05-0.01
EBITDA-2.05-1.91-1.52-1.91-1.71-2.00-1.52-0.20
Non-Operating Income (Expense)0.030.070.070.050.030.080.100.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.140.140.190.170.340.230.270.25
Price To Sales Ratio8.597.8411.0112.187.2111.3514.949.12
Gross Margin-2.4028.7231.9912.0736.5224.3756.8479.78
Operating Margin-212.82-172.13-269.65-164.23-177.21-507.00-186.15-10.04
Net Margin-220.98-175.95-277.13-169.67-185.57-515.17-189.74-10.39
Shares Outstanding36.4436.4436.1936.1930.1430.0929.8429.59
Market Capitalization14.6629.8834.0242.7029.7940.6251.7830.66

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments8.559.267.2612.6420.2629.0934.2241.2047.69
Short Term Receivables1.130.260.480.390.370.411.141.120.76
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.220.300.330.390.380.280.280.431.17
Total Current Assets9.909.838.0713.4221.0129.7835.6442.7549.62
Net Property, Plant & Equipment0.040.090.140.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.280.280.281.510.000.92
Long-Term Note Receivable-----0.000.250.50-
Other Assets0.010.010.010.010.010.010.050.050.21
Total Assets9.959.938.2213.7121.3030.0737.4543.3050.74
Short Term Debt Incl. Current Port. of LT Debt0.030.050.050.000.000.000.000.000.00
Accounts Payable0.850.340.581.071.360.900.790.310.52
Income Tax Payable-------0.000.10
Other Current Liabilities2.802.051.631.381.190.720.800.540.15
Total Current Liabilities3.692.452.252.452.561.631.590.850.77
Long Term Debt5.035.010.090.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.180.350.000.000.000.00
Total Liabilities8.717.462.342.632.911.631.590.850.77
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1.232.475.8811.0918.3928.4535.8642.4549.98
Total Shareholders Equity1.232.475.8811.0918.3928.4535.8642.4549.98
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1.232.475.8811.0918.3928.4535.8642.4549.98
Total Liabilities & Stockholders Equity9.959.938.2213.7121.3030.0737.4543.3050.74
Book Value Per Share0.030.080.200.390.651.031.311.591.76
Tangible Book Value Per Share0.030.080.200.390.651.031.311.591.76
Full-Time Employees567-79987
Price to Book Ratio-5.5915.186.062.786.945.203.951.190.77
Return on Assets-74.11-64.01-61.97-55.61-50.89-27.62-20.58-12.10-3.90
Return on Equity-397.80-139.16-80.11-66.05-55.81-29.00-21.22-12.32-3.97
Return on Invested Capital-117.67-77.64-113.88-87.80-71.07-32.78-23.16-13.41-4.27
Quick Ratio2.684.013.585.488.2218.3222.4450.3164.53
Current Ratio2.684.013.585.488.2218.3222.4450.3164.53

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-7.62-7.36-5.81-6.80-9.74-13.07-9.33-8.31-5.69
Other Funds (Non Cash)0.691.001.080.211.970.611.761.401.16
Funds from Operations-6.93-6.36-4.73-6.58-7.76-12.47-7.56-6.91-4.53
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.480.660.75-0.14-0.321.190.991.130.12
Income Taxes Payable-------0.00-0.10
Cash from Operating Activities-7.40-5.70-3.97-6.73-8.08-11.28-6.57-5.78-4.41
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments1.470.08-1.887.45-2.375.2222.127.713.33
Purchase of Investments-2.69-5.95-7.34-3.00-9.87-11.28-17.64-47.62-49.73
Sale Or Maturity of Investments4.166.035.4710.457.5016.5139.7655.3253.06
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities1.470.08-1.887.45-2.375.2222.127.713.33
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.944.960.020.000.541.230.260.55-2.30
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-2.30
Sale of Common Pref Stock4.944.960.020.000.541.230.260.550.00
Proceedsfrom Stock Options4.944.940.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.005.820.000.000.000.000.000.00
Change in Long Term Debt0.000.005.820.000.000.000.000.000.00
Issuance of Long Term Debt0.000.005.820.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities4.944.965.850.000.541.230.260.55-2.30
Exchange Rate Effect-0.000.00-0.01-0.00-0.04-0.060.01-0.04-0.02
Net Change in Cash-0.99-0.65-0.010.72-9.95-4.8915.812.44-3.40
Free Cash Flow-7.40-5.70-3.97-6.73-8.08-11.28-6.57-5.78-4.41
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4.676.528.5510.256.577.35
Short Term Receivables1.321.011.130.950.750.24
Inventories0.000.000.000.000.000.00
Other Current Assets0.420.170.220.340.080.21
Total Current Assets6.417.709.9011.557.417.81
Net Property, Plant & Equipment0.010.020.040.050.070.08
Total Investments and Advances0.110.070.000.060.650.00
Other Assets0.010.010.010.010.010.01
Total Assets6.547.819.9511.678.147.89
Short Term Debt Incl. Current Port. of LT Debt0.010.020.030.050.060.06
Accounts Payable0.821.060.850.710.740.45
Other Current Liabilities3.062.102.803.302.871.46
Total Current Liabilities3.883.183.694.053.661.96
Long Term Debt5.045.035.035.015.015.01
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities8.928.228.719.078.676.97
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-2.39-0.411.232.61-0.530.92
Total Shareholders Equity-2.39-0.411.232.61-0.530.92
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-2.39-0.411.232.61-0.530.92
Total Liabilities & Stockholders Equity6.547.819.9511.678.147.89
Book Value Per Share-0.07-0.010.030.07-0.020.03
Tangible Book Value Per Share-0.07-0.010.030.07-0.020.03
Full-Time Employees--5---
Price to Book Ratio-5.5924.0813.05-67.1232.2616.30
Return on Assets-103.88-92.86-74.11-65.38-59.42-56.64
Return on Equity--2,826.92-397.80-244.15-422.64-214.26
Return on Invested Capital-80.03-42.26-25.04-25.93-40.07-34.18
Quick Ratio1.652.422.682.852.023.98
Current Ratio1.652.422.682.852.023.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.12-1.95-1.57-1.98-1.79-2.03
Other Funds (Non Cash)0.160.130.210.190.360.23
Funds from Operations-1.97-1.82-1.35-1.78-1.43-1.79
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.15-0.14-0.42-0.071.30-0.16
Cash from Operating Activities-1.82-1.96-1.77-1.85-0.13-1.95
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-0.361.270.470.09-0.960.48
Purchase of Investments-0.73-0.57-0.86-0.53-3.10-1.46
Sale Or Maturity of Investments0.371.831.330.622.141.94
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.361.270.470.09-0.960.48
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.00-1E-064.940.000.02
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.00-1E-064.940.000.02
Proceedsfrom Stock Options0.000.00-1E-064.940.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.00-1E-064.940.000.02
Exchange Rate Effect0.00-0.00-0.00-0.000.000.00
Net Change in Cash-2.17-0.70-1.303.18-1.09-1.44
Free Cash Flow-1.82-1.96-1.77-1.85-0.13-1.95

Revenue breakdown

Grant2025: 1.86M
License2024: 1.89M 2025: 265.00K
Research and Development2024: 1.61M 2025: 967.31K
United States2024: 3.50M 2025: 3.09M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.27%0.1M30.8M165.10K
2026-10-150.63%0.2M30.8M188.23K
2026-09-300.58%0.2M30.8M222.44K
2026-09-150.74%0.2M30.8M220.61K
2026-08-310.58%0.2M29.9M214.41K
2026-08-140.55%0.2M29.9M352.15K
2026-07-310.19%0.1M27.2M331.31K
2026-07-150.31%0.1M27.1M308.06K
2026-06-300.65%0.2M27.1M259.46K
2026-06-150.55%0.1M27.1M246.78K
2026-05-292.30%0.6M27.1M233.17K
2026-05-150.27%0.1M27.1M78.95K
2026-04-300.21%0.1M27.1M73.32K
2026-04-150.31%0.1M27.1M65.82K
2026-03-310.48%0.1M27.0M69.08K
2026-03-130.25%0.1M26.8M65.43K
2026-02-270.35%0.1M26.8M193.42K
2026-02-130.41%0.1M26.8M212.83K
2026-01-300.52%0.1M26.8M225.79K
2026-01-150.55%0.1M26.8M231.07K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.050.0002,1170.000.0000.0000.000
call5.000.002.950.0010.7380.000.000.245-0.0120.000
call7.500.000.950.0011.6760.000.000.236-0.0120.000
put2.500.204.902.250.0002.000.00-0.735-0.0100.000
put5.004.305.104.650.0002.000.00-0.755-0.0110.000
put7.506.809.507.200.0000.000.00-0.764-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-15SCHEDULE 13GSEC
2026-09-258-KCurrent report2026-09-25SEC
2026-09-18EFFECTEffectiveness filing by commission orderSEC
2026-09-18424B3SEC
2026-09-11S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-17SCHEDULE 13G/ASEC
2026-08-148-KCurrent report2026-08-13SEC
2026-08-13424B5SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-22SEC
2026-07-248-KCurrent report2026-07-24SEC
2026-07-21144Filing for proposed sale of securities under Rule 144.SEC
2026-07-064Statement of changes in beneficial ownership of securities2024-03-08SEC
2026-07-06SCHEDULE 13G/ASEC
2026-06-228-KCurrent report2026-06-18SEC
2026-06-18DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-188-KCurrent report2026-06-18SEC
2026-06-158-KCurrent report2026-06-15SEC
2026-05-288-KCurrent report2026-05-28SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-12DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-12SEC
2026-05-11SCHEDULE 13G/ASEC
2026-05-11SCHEDULE 13GSEC
2026-05-01PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-01SEC
2026-04-3010-K/A2025-12-31SEC
2026-03-308-KCurrent report2026-03-27SEC
2026-03-258-KCurrent report2026-03-25SEC
2026-03-2510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-0700124.96K3
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.55%
CHAPIN DAVIS, INC.2.35%
APIS CAPITAL ADVISORS, LLC2.21%
TRUIST FINANCIAL CORP0.81%
GEODE CAPITAL MANAGEMENT, LLC0.67%
BlackRock, Inc.0.54%
MARATHON CAPITAL MANAGEMENT0.39%
VANGUARD FIDUCIARY TRUST CO0.38%
Sage Mountain Advisors LLC0.27%
RENAISSANCE TECHNOLOGIES LLC0.22%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.60%
VANGUARD EXTENDED MARKET INDEX FUND0.95%
Fidelity Extended Market Index Fund0.31%
Fidelity Series Total Market Index Fund0.09%
Fidelity Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.05%

OakChart. DYAI. Cached 15 minutes.